The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 20, 2009
Filed:
May. 11, 2005
Patricia A. Billing-medel, Gurnee, IL (US);
Maurice Cohen, Highland Park, IL (US);
Tracey L. Colpitts, Round Lake, IL (US);
Paula N. Friedman, Deerfield, IL (US);
Julian Gordon, Lake Bluff, IL (US);
Edward N. Granados, Vernon Hills, IL (US);
Steven C. Hodges, Buffalo Grove, IL (US);
Michael R. Klass, Libertyville, IL (US);
Jon D. Kratochvil, Kenosha, WI (US);
Lisa Roberts-rapp, Gurnee, IL (US);
John C. Russell, Kenosha, WI (US);
Stephen D. Stroupe, Libertyville, IL (US);
Patricia A. Billing-Medel, Gurnee, IL (US);
Maurice Cohen, Highland Park, IL (US);
Tracey L. Colpitts, Round Lake, IL (US);
Paula N. Friedman, Deerfield, IL (US);
Julian Gordon, Lake Bluff, IL (US);
Edward N. Granados, Vernon Hills, IL (US);
Steven C. Hodges, Buffalo Grove, IL (US);
Michael R. Klass, Libertyville, IL (US);
Jon D. Kratochvil, Kenosha, WI (US);
Lisa Roberts-Rapp, Gurnee, IL (US);
John C. Russell, Kenosha, WI (US);
Stephen D. Stroupe, Libertyville, IL (US);
Abbott Laboratories Inc., Abbott Park, IL (US);
Abstract
A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as BS106 and transcribed from breast tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer. Also provided are antibodies which specifically bind to BS106-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BS106 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.